Skip to main content
. 2019 Jul 18;11(4):390–396. doi: 10.3892/mco.2019.1899

Table I.

Baseline characteristics (before salvage-line treatment).

Previous chemotherapy and reason for discontinuation All patients (n=17), no. (%)
Fluoropyrimidine
  Refractory 17 (100)
  Intolerant 0
Oxaliplatin
  Refractory 16 (94)
  Intolerant 1 (6)
Irinotecan
  Refractory 15 (88)
  Intolerant 2 (12)
Angiogenesis inhibitor
  Refractory 17 (100)
  Intolerant 0
Anti-EGFR antibody
  Refractory 8 (47)
  Intolerant 1 (6)
RAS mutational status
  Wild-type 9 (53)
  Mutant 8 (47)

EGFR, epidermal growth factor receptor.